Beyond LC-FAODs, medium-chain acylcarnitines may provide therapeutic value in a range of other metabolic disorders that have failed to respond to triheptanoin, such as McArdle’s disease, phosphofructokinase deficiency, GLUT1 deficiency, pyruvate carboxylase deficiency, and alternating hemiplegia of childhood (48–52). Here, PC is linked to hyperinsulinemic hypoglycemia, familial, 4.